Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06637150 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer

Name: Dalpicilib-Enhanced vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer — clinical trial record (NCT06637150)
Creator: DataLookout
License: https://creativecommons.org/licenses/by/4.0/

StatusRecruiting

PhasePhase 3

SponsorFudan University

Started2025-01-09

View on ClinicalTrials.gov ↗

Amendment history

2026-09-30

Enrollment reopened

Fudan University

624 trials monitored

See 9 trials at risk

Breast Cancer

5,180 trials monitored

See 256 trials at risk

This study aims to conduct a randomized controlled clinical trial to compare the efficacy and safety of dalpicilib combined with endocrine therapy versus standard endocrine therapy in ER-positive, HER2-negative, lymph node-negative patients with risk factors, in order to further optimize the regimen for adjuvant endocrine therapy in breast cancer.

Trial Details

NCT Number	NCT06637150
Lead Sponsor	Fudan University
Conditions	Breast Cancer
Enrollment	1,388 participants
Start Date	2025-01-09
Primary Completion	2030-09-30 (estimated)
Study Completion	2030-09-30 (estimated)
Updated on ClinicalTrials.gov	2026-09-29